> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-65/
- Published: 2022-03-06T12:00:00.000Z
- Updated: 2026-09-14T17:35:21.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138963

**PerkinElmer** has entered into a definitive agreement to acquire **EuroImmun Medical Diagnostics** for $1.3 billion in cash. EuroImmun has expertise and capabilities across immunology, cell biology, histology, biochemistry and molecular biology.

**Bristol-Myers Squibb** has agreed to sell its small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland to **SK Biotek**. The companies intend to complete the deal by the fourth quarter, at which time SK Biotek will continue to manufacture the current portfolio of small molecule pharmaceutical products at the site.

**Windtree Therapeutics** and **Lee’s Pharmaceutical Limited** have entered into an exclusive license and collaboration agreement for developing KL4 surfactant products in select Asian markets using Windtree’s proprietary KL4 surfactant and aerosolization technologies. The agreement includes Aerosurf, as well as the non-aerosol products Surfaxin and Surfaxin LS. Also, Windtree has granted Lee’s an exclusive license to manufacture KL4 surfactant in China for use in non-aerosol surfactant products in the licensed territory. Under the agreement, Lee’s has agreed to pay Windtree and upfront fee of $3 million, and it will be eligible for up to $37.5 million in contingent clinical, regulatory and commercialization milestone payments.

**Stryker Corp.** has agreed to acquire medical imaging solutions company **Novadaq Technologies** for about $701 million. Novadaq is a developer of fluorescence imaging technology that provides surgeons with visualization of blood flow in vessels